Bio-Techne Corp
TECH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$93.00 | Wfvfvtq | Bshnkvdxcl |
Bio-Techne Begins Fiscal 2021 on Track, Benefiting From Capacity Growth and Coronavirus Research
Narrow-moat Bio-Techne reported strong fiscal first-quarter earnings, with year-over-year organic revenue up 10% and EPS of $0.83, up from $0.37 last year. While revenue is tracking slightly ahead of our full-year forecast, we still expect net income and cash flow near our full-year expectations, and we maintain our $184 fair value estimate.